Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selexipag add-on therapy in children with pulmonary arterial hypertension
2019-002817-21Phase 3Active
- Sponsor
- Actelion Pharmaceuticals Ltd
- Start
- Oct 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in pulmonary arterial hypertension (PAH) comparing Selexipag + standard of care with Placebo + standard of care (2 arms). Primary endpoint: Time to disease progression. Started Oct 2019; status: active.
02
Drugs
selexipag
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on 2019-002817-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-002817-21.